Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
ViiV Healthcare announces FDA approval of Cabenuva, the first & only complete long-acting regimen for HIV treatment
-
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium
Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers
-
Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment.
-
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
Global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalised adults with COVID-19
-
FDA approves GSK’s BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
Approval builds on nearly 10 years of experience in lupus
-
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly
Phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years
-
FDA accepts GSK’s filing of Nucala (mepolizumab) for use in chronic rhinosinusitis with nasal polyps
If approved, Nucala would be the only treatment approved in the US for use in four eosinophil-driven diseases.
-
GSK Consumer Healthcare Partners with Direct Relief to Donate $1 Million to Support Frontline Healthcare Workers
GSK donates on behalf of consumers to make sure healthcare workers have the supplies they need as the COVID-19 pandemic continues
-
GSK starts phase 3 study of RSV maternal candidate vaccine
RSV is a leading cause of respiratory infections such as bronchiolitis and viral pneumonia in infants.
-
GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age
The results of the TEACH study were presented during the American Society of Tropical Medicine & Hygiene 2020 virtual annual meeting.
-
GSK awards Greater Philadelphia nonprofits making a powerful IMPACT on health outcomes now more than ever
Ten local nonprofits were awarded $40,000 each in recognition of their outstanding contributions to a healthier Philadelphia region.
-
ViiV Healthcare announces results of the PROgress study demonstrating that the inclusion of patient reported outcomes into clinical practice can improve HIV care
ViiV Healthcare announces results of the PROgress study
-
ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention
This is intended to facilitate the development and expedite the review of drugs that address serious or life-threatening medical conditions.
-
GSK awards Triangle nonprofits making a powerful IMPACT on health outcomes now more than ever
GSK IMPACT Awards is a highly competitive program recognizing organizations that are working with the community to improve health.
-
GSK presents Phase 2b data on linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis (PBC)
The Phase 2b GLIMMER study was presented today at The Liver Meeting® 2020.
-
ViiV Healthcare announces CHMP positive opinion for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe
This CHMP positive opinion paves the way to expand the use of dolutegravir in a younger population.
-
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial with GSK’s pandemic adjuvant.
-
GSK highlights progress from the BLENREP (belantamab mafodotin-blmf) development programme in multiple myeloma at ASH Annual Meeting
Studies presented will demonstrate belantamab mafodotin's potential in combination with standard therapies in earlier lines of treatment.
-
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women
The study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).
-
GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030
The new goals support GSK's aim to create long-term value for shareholders and meet the needs of society.
